Medpace Holdings (MEDP)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- CRO Clinical Operationssrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 11/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 6.94% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Don’t Chase Medpace Stock Here Despite Its Strong Technical Momentum
- CON vs. MEDP: Which Stock Should Value Investors Buy Now?
- Medpace (MEDP) Dips More Than Broader Market: What You Should Know
- Medpace (MEDP) Stock Declines While Market Improves: Some Information for Investors
- Medpace (MEDP) Rises As Market Takes a Dip: Key Facts
- CON or MEDP: Which Is the Better Value Stock Right Now?
- Medpace Holdings, Inc. to Report Third Quarter 2026 Financial Results on October 21, 2026
- Projected EPS and Revenue Gains Might Change The Case For Investing In Medpace Holdings (MEDP)
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Medpace Holdings.
Full MEDP Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.